NCT06725706 · RECRUITING
Beta Amyloid PET/CT in Various Aβ-Related Disease
This trial is testing whether two radioactive tracers — 18F-92/AV45 and 11C-PIB — can be used in PET/CT brain scans to detect amyloid deposits in people with various neurodegenerative or tumor-related conditions. It is an imaging study, not a treatment. The phase is unspecified, and details in the source are limited, so a full picture of the research design is not available.
Eligibility criteria
Inclusion Criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-06-04